SIC
AYTU icon

SJS Investment Consulting’s AYTU BioPharma AYTU Stock Holding History

SJS Investment Consulting’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$6 – 1562
2025
Q1 		$6 Hold
5
– – ﹤0.01% 1595
2024
Q4 		$9 Hold
5
– – ﹤0.01% 1591
2024
Q3 		$12 Hold
5
– – ﹤0.01% 1648
2024
Q2 		$15 Buy
+5
New +$15 ﹤0.01% 1649

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SJS Investment Consulting's AYTU Position: Q2 2025 in Review

SJS Investment Consulting sold out of AYTU BioPharma (AYTU) in Q2 2025, closing a stake of 5 shares — an estimated $6 sold.

SJS Investment Consulting first reported a position in AYTU in Q2 2024 and held it in 4 quarters. The position peaked at $15 in Q2 2024. 32 funds tracked by Wall St. Rank hold AYTU as of Q2 2025.

  • SJS Investment Consulting reported no remaining AYTU BioPharma position as of Q2 2025 after selling out during the quarter.
  • SJS Investment Consulting sold 5 AYTU BioPharma shares in Q2 2025, an estimated $6.
  • SJS Investment Consulting first reported a position in AYTU BioPharma in Q2 2024 and held it in 4 quarters.
  • SJS Investment Consulting's AYTU BioPharma position peaked at $15 in Q2 2024.
  • 32 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2025.

Based on SJS Investment Consulting's 13F filing for Q2 2025, filed 15 Jul 2025.